Orchid Chemicals filed a TM-16 in 2003 to record itself as proprietor of “METO” — but the Registry issued the certificate in the old name and sat on the amendment. When Orchid sued “METOX” in 2012, the Madras High Court found it had no standing to sue at all. A cautionary tale of Registry delay and generic pharma marks.
The facts
Orchid Chemicals & Pharmaceuticals (via its division Mano Pharma, per a 2003 agreement) filed to register “METO”, and lodged a Form TM-16 on 24.02.2003 to amend the applicant’s name to “Mano Pharma (a Division of Orchid Chemicals…).” The Registry, without recording the TM-16, issued the certificate on 24.02.2005 in the name “M/s Mano Pharmaceuticals Private Limited.”
The defendant, Wockhardt, adopted “METOX” for a pharmaceutical product for the same ailment. Orchid sent a notice (April 2011) and sued for infringement in January 2012. A Legal Use Certificate reflecting the corrected name issued only on 07.02.2012 — after the suit.
The single judge dismissed the injunction — the assignment procedure wasn’t followed, and the marks weren’t similar, “METO” being derived from “Metoprolol” and thus generic/publici juris. Orchid appealed.
The ruling
The Madras High Court dismissed the appeal, on several grounds:
- No locus standi. The TM-16 was still pending and the certificate stood in the old name when the suit was filed; there was no registered assignment as the Act mandates. Without a proper assignment, Orchid had no standing to sue for infringement of “METO.”
- “METO” is generic. In pharma, generic terms derived from the molecule (Metoprolol succinate) are common and unavoidable; the suffix “X” in METOX made the marks phonetically, visually and structurally distinct.
- Schedule H drugs. Both are prescription drugs handled under a trained physician’s prescription, so buyers/users wouldn’t be confused.
- Sections 28–30. Since “METO” was publici juris and in the public domain even before Orchid’s application, Section 30 limits applied — no exclusive right under Section 28, hence no infringement under Section 29. Section 29 is subject to Section 30, and Section 28 is subject to other provisions.
The lesson
Orchid was, in effect, penalised for the Registry’s delay — the name change it had sought back in 2003 was still pending recordal years later, leaving it without standing when it needed to sue. Two lessons stand out:
- Follow the mandatory assignment procedure and confirm the recordal is complete before enforcing.
- Generic pharma prefixes are weak — a mark drawn from a drug molecule (with a distinguishing suffix) is hard to monopolise.
The takeaways
- Standing depends on a completed recordal — a pending TM-16/assignment can leave you unable to sue.
- Confirm the register reflects you as proprietor before filing suit.
- Molecule-derived marks are publici juris — “METO” from Metoprolol couldn’t be monopolised.
- Prescription (Schedule H) context reduces confusion — physicians mediate the purchase.
Frequently asked questions
Why did Orchid Chemicals lose the METO v. METOX case? Its name-change (TM-16) was still pending and the registration stood in the old name when it sued, so it lacked locus standi; and “METO” was held generic/publici juris.
Can a mark derived from a drug molecule be monopolised? Generally not — such prefixes are common and unavoidable in pharma; a distinguishing suffix (like “X” in METOX) makes the marks dissimilar.
How do Sections 28, 29 and 30 interact here? Exclusive rights under Section 28 and infringement under Section 29 are subject to the Section 30 limits; since “METO” was publici juris, no exclusive right or infringement arose.
What’s the practical lesson on assignments? Complete the mandatory assignment/recordal procedure and confirm the register reflects you as proprietor before suing for infringement.
Legislation referred to
- The Trade Marks Act, 1999